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Endogenous retroviruses present in the human genome provide a rich record of ancient 
infections. All presently recognized elements, including the youngest and most intact 
proviruses of the Human Endogenous Retrovirus-K(HML-2) family, have suffered 
postinsertional mutations during their time of chromosomal residence and genes encoding the 
envelope glycoprotein (Env) have not been spared these mutations. In this study we have, for 
the first time, reconstituted an authentic Env of a HERV-K(HML-2) provirus by back-
mutation of putative postinsertional amino acid changes of the protein encoded by HERV-
K113. Supported by codon-optimized expression we demonstrate that the reconstituted Env 
has regained its ability to be incorporated into retroviral particles and to mediate entry. The 
original ancient HERV-K113 Env is synthesized as a moderately glycosylated gp95 precursor 
protein cleaved into surface (SU) and transmembrane (TM) subunits. Of the nine N-linked 
oligosaccharides, four are part of the TM subunit contributing 15 kDa to its apparent 
molecular mass of 41 kDa. The carbohydrates as well as the cytoplasmic tail are critical for 
efficient intracellular trafficking, processing, stability and particle incorporation. Whereas 
deletions of the carboxy-terminal six residues completely abrogate cleavage and virion 
association, more extensive truncations slightly enhance incorporation but dramatically 
increase the ability to mediate entry of pseudotyped lentiviruses. Although the first HERV-
K(HML-2) elements infected human ancestors about 30 million years ago, our findings 
indicate that their glycoproteins are in most respects remarkably similar to classical 































Retroviruses that infect germ line cells or their precursors can become vertically transmitted 
genetic elements and spread in a host population during subsequent generations (35). About 
8% of the human genome consists of stably integrated endogenous retroviruses acquired 
during early and more recent evolution by our primate and hominid ancestors. These fossils 
are grouped into several distinct families (2, 42). Their sequence and genomic structure 
typically resemble one of the genera of current exogenous retroviruses providing an 
exceptional archive for the study of many aspects of viral and host co-evolution and its 
dynamics (25). In contrast to humans, several animals including mice and sheep contain 
replication competent present-day exogenous and endogenized forms of the same retrovirus 
(1, 10). The most striking example is the koala, a species with a profound ongoing 
endogenization burst with a highly oncogenic gammaretrovirus (52).  
The most recently integrated human elements belong to the betaretrovirus-like HERV-
K(HML-2) family (7, 25, 54). Infectious viruses of this family appear to have started invading 
the chromosomes before the evolutionary split of Old World monkeys and hominoids about 
30 million years ago (41, 50). Several of its members are human specific, indicating a 
continuing active replication in our ancestors following the deviation of the chimpanzee 
lineage 5-6 million years ago (4, 7, 12). The recent acquisition of several HERV-K(HML-2) 
elements is further substantiated by the lack of fixation (not present in all individuals) (6, 54). 
However, during their residency in the host genome every one of the currently known 
proviruses has suffered from mutations, deletions or recombination events. In many cases 
homologous recombination has left only a single LTR at the integration site (31). None of the 
more complete proviruses appear to be replication competent, although some of them have 
retained the capacity to form particles (8, 11). Recently, infectious HERV-K(HML-2) viruses 
have been produced by generating consensus sequences based on human specific elements 
and, in an alternative approach, by assembling functional regions of three authentic proviruses 



























into a single element (21, 39). These studies clearly demonstrate that (i) HERV-K(HML-2) is 
able to form viral particles infecting human cells and (ii) certain recombination events such as 
template switching during reverse transcription or gene conversion might re-establish fully 
functional chimeric HERV-K(HML-2) elements by combining conserved sequences from 
partially crippled proviruses.  
One of the best preserved full length HERV-K(HML-2) elements is HERV-K113 (5, 54). Due 
to its low prevalence of less than 20% it escaped recognition by the Human Genome Project 
and the provirus was identified in a human BAC library on chromosome 19p13.11 of an 
unknown DNA donor (54). As previously reported by us and by others, despite a functional 
LTR promoter and open reading frames for all proteins, a few substitutions in the reverse 
transcriptase and one critical substitution in the gag gene of the provirus contribute to its lack 
of replication (5, 29, 54). In addition, the envelope protein of the cloned HERV-K113 
provirus is not incorporated into viral particles, suggesting further postinsertional damage by 
mutation(s) (5, 20). These changes are not necessarily present in all HERV-K113 variants in 
the human population since some degree of polymorphism between carriers from different 
ethnic groups can be expected (44). Thus functional HERV-K113 envelope genes might still 
exist in some humans, as has been demonstrated for the related HERV-K108 element (20).  
Retroviral envelope proteins are synthesized as fusion inactive precursor glycoproteins which 
trimerize and get cleaved by furin-like endopeptidases in the Golgi compartment of the cell 
into SU and TM subunits (32, 38). The mature N-glycosylated trimeric proteins eventually 
reach the cell membrane where they become incorporated into particles (18). The cytoplasmic 
domain of the protein has been shown to be critical for transport, incorporation and 
fusogenicity of virions (9, 13, 15, 37). Some retroviruses release a short carboxy-terminal  
R-peptide, a step necessary for full fusogenic activity of the glycoprotein (27). With the 
exception of the syncytin-1 and -2 glycoproteins which are the fusogenic envelope proteins of 
a HERV-W and HERV-FRD element involved in the formation of the placental 













syncytiotrophoblast layer, the envelope proteins of other HERVs are poorly characterized 
(14).  
In the present report we have identified inactivating mutations in the envelope gene of a 
present day HERV-K113 provirus. All or almost all of the changes most likely occurred 
gradually following integration in the genome more than a million years ago. In this case the 
already endogenous virus was probably able to replicate for a certain period of time, although 
damaging pre-integrational mutations introduced by the RNA polymerase or during reverse 
transcription by errors of the enzyme and by the action of APOBEC proteins can not be 
completely ruled out. We reconstituted the original sequence presumed to exist at the time of 
integration. Facilitated by codon-optimized expression we investigated various aspects of the 
glycoprotein and carboxy-terminal truncation mutants in terms of cleavage, N-glycosylation, 
incorporation into viral particles and mediation of viral entry into target cells.  
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HEK 293T, Tera-1, HeLa and CrFK cells were cultured in complete Dulbecco's Modified 
Eagle Medium (DMEM) containing 10% FBS, penicillin (50 U/ml), streptomycin (50 µg/ml) 
and L-glutamine (2 mM). 
 
Codon optimization, mutagenesis and cloning of Env constructs. 
A synthetic version of the HERV-K113 (GenBank AY037928) Env protein, optimized for 
expression in mammalian cells, was designed and synthesized by Geneart (Regensburg, 
Germany). The codon optimized sequence, coEnv (Fig. S1), was cloned into a C-terminal V5-
tag-containing pcDNA3 expression vector (Invitrogen) using the EcoRI/ NotI cleavage sites. 




(pcDNAoricoEnv-V5) as well as all derived mutants were generated using the QuickChange 
Multi Site-Directed Mutagenesis Kit or the QuickChange Site-Directed Mutagenesis Kit 
(Stratagene) and primer pairs listed in Fig. S2. These mutants include the N-glycosylation 
deficient variant oricoEnvGly-, the cleavage site mutants oricoEnvCS- and 
oricoEnvCS_MMTV, the C-terminal truncation mutants oricoEnv659-699, oricoEnv680-
699, oricoEnv693-699 and the envelope proteins without V5-tag. The last four were 
generated by the introduction of stop codons at the respective positions in pcDNAoricoEnv-
















Envelope expression analysis. 
For Env expression analysis, 4 x 106 cells grown in 100 mm dishes were transfected with the 
appropriate expression plasmid using the calcium phosphate method. Cells were lysed in  
500 µl lysis buffer (1% Triton X-100, 50 mM Tris HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 



























and protease inhibitor mix (Roche)) and cell debris was removed by centrifugation. For 
immunoprecipitation experiments 25 µl of V5 sepharose (Sigma) were added to the lysate 
and incubated on an overhead shaker for 4 h. The sepharose beads were washed 5 times with 
washing buffer (1% Triton X-100, 50 mM Tris HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 
0.02% SDS and protease inhibitor mix), mixed with Laemmli sample buffer (BioRad), briefly 
boiled and pelleted. For simple immunoblotting, the cleared lysates were directly mixed with 
sample buffer and cleared by centrifugation before being subjected to SDS-PAGE. The 
separated proteins were transferred to a polyvinylidene diflouride membrane (Roth) using the 
semi dry transfer method. The membranes were blocked in blocking buffer (PBS, 5% 
skimmed milk powder, 0.1% Tween) and finally incubated with specific antibodies. An V5- 
HRP antibody (Invitrogen) was used for quantification. It was detected by a secondary Alexa 
Fluor 680 donkey anti-mouse IgG before measurement of band fluorescence intensity using 
an Odyssey Scanning and Analysis (LI-COR) unit. In experiments without quantification, 
V5-HRP or TM specific (HERM-1811-5, Austral Biologicals) monoclonal antibodies were 
used in conjunction with an HRP-conjugated secondary anti-mouse antibody. Bands were 
visualized using Enhanced Chemiluminescence Reagents (Pierce).  
 
Immunofluorescence microscopy. 
Cells (1 x 105) were grown in chamber slides (Nalge Nunc) and transfected with 0.2 µg of 
plasmid DNA using Effectene Reagent (Qiagen). After 48 h, cells were fixed with 2% 
paraformaldehyde in PBS for 30 min, rinsed briefly with PBS, permeabilized with PBS-
buffered 0.5% Triton-X 100 and again washed 3 times with PBS. After blocking with Marvel 
(1% non fat milk in PBS) for 20 min, cells were incubated with primary antibodies diluted in 
blocking buffer for 60 min at 37 °C. HERM-1811-5 (Austral Biologicals) or αV5 (Serotec) 
were used as primary antibodies. The slides were washed 3 times with PBS and a Cy3-
conjugated mouse specific secondary antibody (Sigma) diluted 1:200 was added for 30 min. 


























After extensive washing the cells were mounted in Mowiol and examined using a Zeiss LSM 
510 confocal laser scanning microscope. 
 
Deglycosylation experiments. 
PNGase F deglycosylation experiments were performed with precipitated V5-tagged envelope 
proteins immunoprecipitated from lysates of transfected cells grown in 6-well plates. Cells 
were lysed 48 h post transfection in 200 µl lysis buffer. The precipitates were briefly boiled in 
1x denaturation buffer at 98 °C for 10 min and 3 µl 10x G7- buffer (New England Biolabs), 3 
µl 10% NP-40 and 1500 units of N-glycosidase F (PNGase F, New England Biolabs) were 
added for digestion. The tubes were incubated for various times at 37 °C and the 
deglycosylation reaction was stopped by adding Laemmli sample buffer (BioRad). The 
proteins were immunoblotted using the V5- HRP specific antibody (Invitrogen).  
To inhibit intracellular N-glycosylation, cells were preincubated for 2.5 h with DMEM 
containing 30 or 50 µg/ml of tunicamycin. After the pretreatment, cells were transfected using 
the Polyfect Transfection Reagent Kit (Qiagen) and incubated for an additional 24 h in 
medium containing tunicamycin before lysis and immunoblotting. 
 
Production of pseudotyped SHIV reporter viruses. 
The SIVmac based retroviral vectors pSIvec1envLuc and pSIvec1ΔenvGFP, the HIV-1-Rev 
expressing plasmid pCMV-Rev and the plasmid pSVIII-ΔKS (expressing a non-functional 
HIV-1 envelope to allow non-specific virus uptake to be determined) are described elsewhere 
(3). To generate infectious SHIV particles capable of a single round of infection, 4 x 106 HEK 
293T cells were transfected with 15 µg of pSIvec1ΔenvLuci, 5 µg pCMV-Rev and 0.5 µg of 
an envelope expression vector in 10 cm dishes using the calcium phosphate method. At 2 days 
post-transfection, supernatants were harvested, centrifuged at 6000 rpm for 10 min and 
















filtered through 0.45 µm pore-sized membranes to remove residual cells. Gag-specific ELISA 
and RT-activity (GE Healthcare) were used to assess and normalize virus preparations. 
 
Ultracentrifugation of cell supernatants. 
Viral particles were concentrated by ultracentrifugation of cell supernatants through a 20% 
sucrose cushion for 2 h, at 4 °C and 175,000g. The viral pellet was resuspended in 50 µl of 
0.05 M Hepes, pH 7.2. 
 
Infectivity assays. 
For entry experiments, CrFK target cells were sown in 6-well plates (600,000 cells/well). The 
next day, cells were rinsed with PBS and incubated with 400 µl normalized virus supernatant 
and 200 µl DMEM for 2 h before addition of 1.5 ml DMEM medium and culturing for 2 days. 
Infection was determined by measuring the luciferase activity in cell lysates using the 
Luciferase Assay System (Promega) according to the manufacture’s instructions. 
 



























Enhanced expression of the HERV-K113 envelope protein. 
The Env of HERV-K(HML-2) is translated from a singly spliced transcript. A second splicing 
event removing large parts of the coding region results in the mRNA for the 
nucleocytoplasmic shuttle protein Rec at the expense of Env (Fig. 1). This internal splicing, 
the low GC content of 42% and the use of rare codons are the most likely causes for the poor 
expression of the HERV-K(HML-2) envelope protein from CMV promoter-driven constructs 
(5). To overcome this limitation for the Env of HERV-K113, which significantly hampers a 
functional characterization of the protein, we have generated a synthetic version optimized for 
expression in mammalian cells by synonymous exchange of 71% of the codons (no change in 
amino acid sequence) and raising the GC content of the sequence to 63%. The codon 
optimization and the concomitant removal of the internal splice sites resulted in a drastic 
increase in expression (over 50-fold) as demonstrated by immunoprecipitation (Fig. 2A) of 
the glycoproteins from transiently transfected HEK 293T cells and by immunofluorescence 
microscopy (Fig. 2B). For immunoprecipitation and detection purposes, a V5-tag that 
increases the molecular size by 1.7 kDa has been fused to the C-terminus of wtEnv and 
coEnv. On immunoblots, specific bands with apparent molecular masses in the range of about 
75-95 kDa and 32-38 kDa are visible (Fig. 2A), sizes that match those expected for the 
glycosylated precursor protein and the transmembrane (TM) subunit (5). 
 
Reconstitution of the ancestral sequence of the HERV-K113 envelope protein. 
We and others have previously reported that the HERV-K113 envelope protein is not 
incorporated into viral particles (5, 20) and it was assumed that the cause lay in 
postinsertional mutations acquired during its time in the human genome. In an approach 
similar to that recently used to generate two related HERV-K(HML-2) consensus sequences 
(21, 39), we aligned the amino acid sequence of HERV-K113 Env with the corresponding 



























sequences of 10 well-preserved human specific elements belonging to this family to identify 
and repair postinsertional amino acid substitutions in the HERV-K113 coEnv protein (Fig. 3). 
To differentiate between authentic polymorphisms in the integrating ancient viruses and 
postinsertional changes, we assumed a nonsynonymous postinsertional mutation if none or 
only one of the aligned proviruses matched the amino acid of HERV-K113 and assumed a 
shared polymorphism if two or more of the elements had the same amino acid as HERV-
K113, even if different from the consensus sequence. Three such variable positions (T137, 
I369 and V676) were identified and left unchanged (Fig. 3). In contrast, 8 putative protein-
relevant postinsertional substitutions were identified, 4 in the SU and 4 in the TM region (Fig. 
3). Using site-directed mutagenesis we reversed these 8 amino acids in the pcDNAcoEnv-V5 
plasmid, taking the consensus amino acids as the originals. The resulting construct, 
pcDNAoricoEnv-V5, encodes a V5-tagged version of the putatively ancestral HERV-K113 
envelope protein existing at the time of integration into a human ancestor. 
 
The original HERV-K113 envelope protein is moderately N-glycosylated.  
We first compared the expression of coEnv (present day) and oricoEnv (original) by 
immunoblotting of lysates from transfected HEK 293T, Tera-1 and HeLa cells. Although both 
glycoproteins had similar levels of expression, considerable differences in the processing and 
migration patterns of the presumed TM subunits were seen. Although the ratio of precursor to 
TM varied somewhat from lysate to lysate, oricoEnv was more efficiently cleaved than coEnv 
in all experiments. The presumed TM subunit of oricoEnv-V5 migrates as a 43 kDa band in 
all cells tested. In contrast, coEnv-V5 is very inefficiently cleaved into a 35 kDa protein in 
Tera-1 cells, and in HEK 293T and HeLa cells a fuzzy doublet of about 33 and 35 kDa can be 
seen (Fig. 4A).  
Differences in the carbohydrate composition of the two proteins were considered to be a 
likely reason for the discrepancy in size. CoEnv contains 10 consensus NXS/T motifs for  



























N-linked glycosylation (23, 55), with two of the sites (N506 and N507) being adjacent  
(Fig. 3). The N506K back mutation altered this motif giving 9 potential sites for N-linked 
carbohydrates in oricoEnv: 5 in the SU subunit and four in the ectodomain of TM (Fig. 4B). 
Treatment of precipitated glycoproteins from transfected HeLa cells with peptide-N-
glycosidase F (PNGase F), which removes all N-linked glycans, decreased the apparent 
molecular weight of the presumed oricoEnv-V5 TM subunit to 28 kDa (Fig. 4C), the size 
calculated for the non-glycosylated TM-V5 subunits. However, the supposed TM doublet of 
coEnv-V5 was also shifted by PNGase F treatment although the deglycosylated proteins 
clearly migrated above 28 kDa, indicating further N-terminal processing sites and a lower 
carbohydrate content of the TM subunit compared to that of oricoEnv. The precursor sizes of 
approximately 95 and 70 kDa are consistent with the molecular masses of the glycosylated 
and non-glycosylated proteins (the theoretical size of the unmodified protein without signal 
peptide is 68 kDa).  
To ascertain the nature of the detected protein bands we incubated pcDNAoricoEnv-V5 
transfected HEK 293T cells with tunicamycin, an agent that prevents the transfer of 
saccharidic units to the nascent peptide chain in the ER. Immunoblot analysis show that 
tunicamycin treatment results in the disappearance of the glycosylated precursor and TM 
bands and instead a protein pattern similar to that observed after PNGase F treatment (70 kDa 
precursor and 28 kDa TM) is seen (Fig. 4D). The TM protein in tunicamycin treated cells is 
barely visible, indicating an inefficient furine protease-mediated cleavage of the non-
glycosylated protein. This assumption is further strengthened by the expression and 
immunoblot analysis of a mutant oricoEnv protein with all nine potential N-glycosylation 
sites mutated by changing the serine or threonine residue of the NXS/T motif into alanine. 
The oricoEnvGly- protein shows a band pattern similar to that already described for cells 
treated with moderate levels of tunicamycin (Fig. 4E). Together, these results illustrate that 
prevention of N-linked glycosylation results in a 70 kDa precursor protein whose processing 



























is extremely inefficient. Furthermore, the strength of a specific 64 kDa band increases with 
treatment. This protein appears to represent an N-terminal truncation product of the 
unglycosylated precursor, suggesting a protective role for the N-terminal glycans against 
cellular proteases and degradation. 
Interestingly, the position of one of the potentially glycosylated asparagines (N461) is only 5 
amino acids upstream of the predicted furin cleavage site (Fig. 4B). An N-glycan at this 
location might influence the processing efficiency of the precursor protein. To test this by 
preventing glycosylation at this position we substituted the serine in the 461NRSKR sequence 
to alanine (461NRAKR). This mutation obliterates the glycosylation signal and changes the 
supposed cleavage site motif of oricoEnv into a sequence matching that of the closely related 
betaretrovirus mouse mammary tumor virus (MMTV) (Fig. 4B). As shown in Fig. 4F, this 
substitution had no significant effect on processing efficiency. In contrast, replacing the 
positively charged amino acids in the cleavage site by alanine (461NASAA mutant) completely 
abolished the release of the 43 kDa TM subunit. This result therefore implies that either N461 
is not glycosylated or that the carbohydrate at this location neither inhibits nor enhances 
processing. Furthermore, the 461NASAA mutant provides further evidence that the 43 kDa 
TM protein is generated by processing at the assumed SU/TM cleavage site. 
 
Incorporation of the reconstituted HERV-K113 Env into lentiviral particles is 
modulated by C-terminal sequences. 
We next investigated whether or not the HERV-K113 oricoEnv protein is incorporated into 
lentiviral particles. Together with vectors for the expression of the lentiviral proteins and the 
packaged RNA containing a luciferase gene, 0.5 g of an Env plasmid of choice were 
included to produce pseudotyped SHIV-reporter particles in transfected HEK 293T cells, as 
described previously (3). Furthermore, for several retroviruses a C-terminal truncation of the 
cytoplasmic tail has been shown to influence particle incorporation and/or fusogenic 


























properties of the envelope protein (13-15). We therefore created three mutants with C-
terminal truncations, namely oricoEnv659-699, oricoEnv680-699 and oricoEnv693-699 
(Fig. 5A), and included them with the cleavage and glycosylation minus mutants 
oricoEnvGly- and oricoEnvCS- in the experiments. All proteins were expressed at 
approximately equivalent levels in HEK 293T cells (Fig. 5B). The Env proteins were detected 
using a commercially available monoclonal antibody that recognizes an epitope in the 
ectodomain of the TM subunit and the changes in size of the truncated TM subunits were 
noticeable for oricoEnv659-699 and oricoEnv680-699 (Fig. 5). Interestingly, no processing 
occurred with the oricoEnv693-699 mutant that lacks just seven amino acids (Fig. 5B, left 
panel). To examine incorporation into virions, the supernatants were harvested, carefully 
clarified and concentrated by ultracentrifugation through a 20% sucrose cushion. Immunoblot 
analysis of the pellets using the TM specific antibody revealed varying degrees of 
incorporation into SHIV particles (Fig 5B, right panel). Whereas no incorporation was 
detectable for coEnv, oricoEnv693-699 and the glycosylation and cleavage deficient 
oricoEnv mutants, substantial incorporation of oricoEnv680-699 and oricoEnv659-699 
was observed at levels approximately 2 and 5 times higher, respectively, than the parental 
oricoEnv. It is of particular interest that the mutant almost completely lacking the cytoplasmic 
tail (oricoEnv659-699) is exclusively incorporated as the cleaved glycoprotein. 
Together, these results demonstrate that progressive truncation of the HERV-K Env 
cytoplasmic tail influences processing and particle association.  
 
The ancestral HERV-K113 envelope protein mediates entry of retroviral particles and 
its infectivity can be augmented by an extensive C-terminal truncation. 
The infectivity of the SHIV-luciferase reporter particles carrying various envelope proteins 
was tested next. The single round entry assays were performed using Crandell feline kidney 


























(CrFK) cells or dog Cf2Th cells as targets and virus suspensions normalized for reverse 
transcriptase activity. CrFK cells have been previously reported to be susceptible to infection 
with HERV-K(HML-2) (39). Although specific entry of virions carrying coEnv or 
oricoEnv693-699 could not be detected (Fig. 6), significant entry was achieved by 
pseudotyping with the ancestral oricoEnv, giving levels of luciferase activity two orders of 
magnitude higher than the background determined with a non-functional HIV envelope 
protein (KS) (3). Similar results were obtained in experiments with Cf2Th cells (data not 
shown). Unexpectedly, the efficiencies of entry with oricoEnv680-699 and oricoEnv659-
699 pseudotypes were even 10 or 100-fold higher, respectively (Fig. 6). In parallel 
experiments using pseudotypes expressing GFP instead of luciferase, flow cytometry revealed 
that up to 30% of the target cells were infected with oricoEnv659-699 (data not shown). 
Therefore, in contrast to the modern proviral HERV-K113 envelope protein, the putative 
ancestral envelope is efficiently incorporated into retroviral particles and mediates entry. 
Removal of the last 7 amino acids of the glycoprotein completely blocked cleavage and 
particle incorporation and although truncation of the cytoplasmic tail by 20 or 42 C-terminal 
amino acids resulted in only a slightly higher incorporation there was a much stronger 
enhancement of virus entry. 
 
Two arginine-to-cysteine mutations are the predominant cause for the loss of coEnv 
function. 
To further analyze the impact of the postinsertional mutations in the env gene of HERV-K113 
we generated coEnv659-699 constructs containing the SU or TM sequences of oricoEnv. 
These two envelope proteins (coEnv659-699 SU-orico and coEnv659-699 TM-orico) did 
not facilitate entry of pseudotyped reporter viruses, indicating that mutations in both the SU 
and the TM subunit of coEnv contribute to the lack of entry (Fig. 7A). Eight oricoEnv659-








699 mutants, each carrying a single reversion, were then generated in order to identify the 
extent with each of the eight postinsertional mutations contributes to the loss of coEnv 
function. Entry experiments using these pseudotyped reporter viruses showed that only the 
R140C mutation in the SU subunit and the R577C mutation in the TM essentially completely 
abolish entry whereas the K506N and P626T mutations each reduce entry by a factor of 
approximately 10 (Fig. 7A). Similar results were obtained with mutants in the context of the 
full length oricoEnv protein (Fig. 7B).  



























Cell entry of retroviruses is triggered by a specific interaction of the viral envelope 
glycoprotein with one or more receptor proteins in the cellular membrane. The receptor 
expression profile largely defines the virus's cellular tropism. Despite being present in many 
healthy and tumorigenic human tissues and being capable of pseudotyping other retroviruses, 
the envelope protein of HERV-K(HML-2) has been only poorly characterized (17, 20). Two 
major obstacles have long hampered the study of the protein's fundamental characteristics: the 
inefficient protein expression in mammalian cells, even when under the control of strong 
promoters, and the uncertainty concerning the impact of postinsertional mutations (53). 
Recently however, recognition that the HERV-K108 glycoprotein has residual functional 
activity plus the in silico generation of consensus prototypic HERV-K(HML-2) sequences 
have added considerably to our basic understanding of the virus and its proteins (20, 21, 39).  
The data presented here describe a strategy to overcome the poor expression and document 
efforts to reconstitute a HERV-K(HML-2) Env protein coded for by the HERV-K113 element 
that originally entered the human germ line as an infectious retrovirus more than 800,000 
years ago (33, 54). This provirus is one of the most studied elements. It has preserved open 
reading frames for all viral proteins, but has been inactivated by postinsertional mutations 
effecting, amongst others, the expression and function of Env (5, 29).  
The use of a synthetic DNA sequence optimized for mammalian cells elevated the expression 
of HERV-K113 Env by a factor of over 50 compared with that of the proviral sequence. 
Codon optimization has previously been successfully used to boost the expression of several 
other retroviral proteins, including envelope glycoproteins (19, 45). Full-length retroviral 
genomes require a balanced expression of their proteins for optimal replication and their 
DNA, RNA and protein sequences are under a multitude of constrains and selective pressures. 
The consequential use of rare codons, low GC content, unstable RNA and internal splicing, 
(e.g. the generation of Rec transcripts from HERV-K env mRNA) results in submaximal 



























levels of expression. A limited expression of toxic viral proteins can as well minimize adverse 
effects on cell viability. Viral RNA is also a target for antiviral responses that result in 
specific transcript degradation and low protein expression. Recently a large number of 
microRNAs has been identified that target exogenous and endogenous retroviruses, including 
HERV-K (28). The role played by such silencing small RNAs in the inefficient expression of 
HERV-K proteins deserves further investigation.  
The efficient expression of the Env protein prompted us to identify and correct mutations that 
have altered the original protein sequence of the primordial infectious retrovirus and to 
perform a comparative study with the contemporary Env. Such sequence changes may have 
been already introduced before integration, e.g. by the RNA polymerase in the producer cell, 
during reverse transcription, as a result of the inherent low fidelity of the enzyme or by the 
action of APOBEC deaminases. Alternatively, the mutations have occurred gradually over 
evolutionary time since integration. Because it is unlikely that there are more than one or two 
RT errors in a single round and as the action of APOBEC deaminases has not been shown to 
significantly effect HERV-K113 in a recent report (40), it is likely that most, if not all, of the 
mutations occurred after integration.  
Although the method used to identify postinsertional changes was based, like those previously 
used to generate consensus sequences (21, 39), on sequence alignments, it also allows likely 
mutations and shared polymorphisms in a minority of elements to be discriminated (29). The 
young age of the 11 proviruses used for alignment makes it very unlikely that the shared 
polymorphisms are the result of matching postinsertional mutations in more than two 
individual proviruses or of ectopic recombination events (30) between the env genes of 
HERV-K113 and two or more of the other aligned elements, although these cannot be 
completely ruled out.  
The assumed shared polymorphisms account for three amino acid differences between the 
reconstituted HERV-K113 Env and the deduced consensus sequence (Fig. 3). In contrast, 



























amongst the aligned sequences eight amino acids are unique to the contemporary HERV-
K113 Env or match with only one element. The corresponding non-synonymous mutations 
were therefore assumed to be postinsertional changes and were inverted to restore the original 
protein sequence. As shown by the immunoblot TM band, the reversions yielding oricoEnv 
altered the protein's N-glycan pattern. Although one consensus N-glycosylation motif in the 
TM subunit was lost by the N506K back mutation, an increase in the apparent molecular mass 
was seen. Aberrant folding and impaired transport through the ER-Golgi compartment are the 
likely reasons for the peculiar glycosylation, migration characteristic in the Western blot, and 
the reduced stability of the modern HERV-K113 Env. This is consistent with the very low 
level of surface expression and lack of incorporation into viral particles (20). In contrast, the 
TM subunit of the reconstituted original protein (oricoEnv) displayed a more regular 
glycosylation pattern, reached the cell surface (data not shown) and was efficiently 
incorporated into lentiviral particles. In agreement with the known consensus sequences for 
HERV-K(HML-2), oricoEnv contains nine potential N-glycosylation sites, 5 in the SU and 4 
in the TM subunit. The number and SU/TM ratio of 5/4 are similar to that of Jaagsiekte sheep 
retrovirus (JSRV; ratio 6/3). The mouse mammary tumor virus (MMTV; ratio 3/2) or syncytin 
1 (HERV-W; ratio 6/1) are less glycosylated (14). Deglycosylation experiments shifted the 
V5-tagged oricoEnv TM by 15 kDa from 43 kDa to 28 kDa. Assuming a reduction of at least 
2.8 kDa per oligosaccharide (14), it is likely that all four N-glycosylations sites predicted for 
TM are modified in HEK 293T cells and probably in most other human cells. The same seems 
also to be true for the five sites in the oricoEnv SU subunit. Focusing on the HERV-K108 
glycoprotein, which contains one additional N-glycosylation site in its SU subunit, 
Dewannieux and colleagues demonstrated a 20 kDa shift following PNGase F digestion (20). 
This result and the size difference between the glycosylated and non-glycosylated precursor 
proteins indicate that most, if not all, theoretical sites carry an N-linked carbohydrate. Of 
particular interest in this respect is N461 that lays only 5 amino acids upstream of the furin 
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cleavage site (461NRSKR). Since cleavage occurs after initial glycosylation, an 
oligosaccharide at this position might influence processing efficiency (55) and indeed, an 
impaired cleavage has previously been shown for HERV-K(HML-2) Env proteins (8). To test 
this, we substituted the serine with alanine, eliminating the glycosylation motif and 
immediately creating the cleavage site of MMTV (26). The mutated protein was cleaved with 
the same efficiency as the oricoEnv protein, indicating that in HEK 293T cells, at least, the 
presence of an N-glycosylation site close to the cleavage site does not impede the furin 
protease or asparagine 461 is not glycosylated. Alternatively, a cleavage enhancement by the 
N-glycan prevention in the 461NRAKR mutant might be exactly balanced by a negative effect 
of the serine to alanine mutation. As tunicamycin treatment or expression of non-glycosylated 
oricoEnv resulted in poor processing and a susceptibility to intracellular proteolysis, it would 
appear that efficient cleavage of Env depends on proper glycosylation. Several studies have 
already described the importance of extensive SU and TM glycosylation for folding, 
transport, processing, fusogenicity and immunological shielding of numerous retroviral 
envelope proteins (36, 47, 49). For HIV-1, which contains between 18 and 33 N-linked 
carbohydrates (4 in TM), mutation of glycosylation sites in gp41 has been shown to lead to a 
considerable inhibition of Env transport, cleavage and fusion activity (16, 23, 55). This 
impediment results from a substantial arrest of the protein in the Golgi (23). Furthermore, 
non-glycosylated HERV-W envelope proteins also remain trapped in the secretory 



























In agreement with these observations and with previously published data, it was not possible 
to demonstrate incorporation of the contemporary HERV-K Env (coEnv) into lentiviral 
particles or the production of infectious virus (5, 20). It is likely that one or both of the 
arginine to cysteine mutations which render the protein non-functional prevent the correct 
folding of the Env protein, which in turn results in aberrant glycosylation and a lack of 
particle incorporation. In contrast to coEnv, pseudotyping of SHIV particles by the ancient 


























oricoEnv was very efficient. The protein was able to efficiently mediate entry into target cells, 
demonstrating a functional reconstitution. In contrast, abrogating N-glycosylation or 
preventing processing into SU and TM subunits by mutation of the cleavage site dramatically 
reduced oricoEnv particle incorporation.  
HERV-K(HML-2) Env has a relatively short putative cytoplasmic tail of only 44 amino acids 
(20) and truncation of the cytoplasmic tail is known to modulate particle incorporation and  
the fusogenicity of retroviral glycoproteins (13, 15, 37). In the case of MLV and related 
gammaretroviruses, the R-peptide, a short C-terminal peptide, is cleaved off by the viral 
protease during maturation, a step necessary for full fusogenicity. Although there is no 
evidence for the presence of an R-peptide in HERV-K(HML-2), we addressed whether 
arbitrary progressive C-terminal truncations of oricoEnv by insertion of stop codons would 
effect Env incorporation and associated viral functions. Surprisingly, the mutant with the 
shortest deletion (seven amino acids) had a late maturation defect with no cleavage or particle 
incorporation. The intermediate truncation of 18 amino acids did not significantly affect 
processing and incorporation efficiency but particle infectivity was increased by a factor of 
10. A further truncation of 41 amino acids, leaving only 3 amino acids of the putative 
cytoplasmic domain, yielded particles bearing approximately 5-fold more Env but having a 
capacity for fusion almost 100-fold higher than with the full-length oricoEnv. Although the 
underlying mechanism for this difference remains unclear, it is possible that the higher 
glycoprotein content with the short-tailed Env helps the budding lentiviral particle by 
reducing the interference between the matrix protein of the nascent Gag shell and the C-
terminal tail (13, 24, 43). Indeed, envelopes with short cytoplasmic tails are known to be 
better incorporated into SIV particles (34, 48). Alternatively, the mutant might have improved 
kinetics of transport and maturation or a lower rate of endocytosis resulting in a higher 
glycoprotein concentration at the budding site.  



















Truncation of the Env cytoplasmic tail has been reported to augment fusogenicity for a 
number of retroviruses (13, 46, 51). For the HERV-K Env it is tempting to speculate that the 
predominant or almost exclusive incorporation of completely processed glycoproteins is one 
reason for the considerably higher infectivity using the short-tailed truncation mutants. Other 
possible explanations include an increased mobility in the viral membrane (which could 
promote Env clustering during fusion) or an inherent structural difference in the TM 
ectodomain that favours fusogenicity (22, 56). Further studies are needed to elucidate the 
exact cause of this enhancement and to determine its relevance for integration into HERV-K 
particles.  
Given the abundance and polymorphism of endogenous retrovirus-K elements in humans and 
other primates it is likely that many more functional HERV-K(HML-2) glycoproteins are to 
be found in several genomes in addition to the known functional HERV-K108 Env. The 
reconstitution and efficient expression of the original ancient HERV-K113 Env protein 
facilitated rational studies of the N-glycosylation, processing, incorporation and mediation of 
entry of this fossil retrovirus. The results show that the protein can pseudotype retroviruses 
and mediate efficient entry into cells. Its use as a functional model protein should assist in the 
search for the cellular receptor and in studies focusing on the pathophysiologic as well as 
physiologic implications of HERV-K(HML-2) Env expression.  
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Fig. 1. Genomic organization of the HERV-K113 provirus and its envelope protein. The Env 
precursor protein is translated from a singly spliced RNA and is composed of the N-terminal 
signalpeptide (SP), the surface glycoprotein (SU) and the transmembrane subunit (TM) 
comprising the hydrophobic membrane spanning domain (MSD). The cleavage site (CS) for 
cellular furine proteases is indicated. The theoretical molecular weights of each subunit (SP, 
TM, SU) as well as the last amino acid of relevant domains are shown. 
 
Fig. 2. Expression of wtEnv and coEnv. HEK 293T cells were transfected with 
pcDNAwtEnv-V5 and pcDNAcoEnv-V5. (A) Western blot analyses of immunoprecipitates 
using an V5-HRP antiserum (1:5000). Assumed precursor proteins at 75-90 kDa and TM 
subunits at 32-38 kDa are visible. Quantification of the band intensities indicates an increase 
in expression of 50-fold or more resulting from Env codon optimization. (B) Immune 
fluorescence analysis of wtEnv and coEnv using an V5-Cy3 antibody. The signal intensity 
and the number of cells expressing Env is significantly higher in cells transfected with coEnv. 
 
Fig. 3. Alignment of the amino acid sequences of 11 HERV-K(HML-2) envelope proteins. 
Sequences of HERV-K101 (AF164609), K102 (AF164610), K104 (AC116309), K107 
(AF164613), K108 (AC072054), K109 (AC055116), K115 (AY037929), Y178333, 
AP000776 and AC025420 are compared to the K113 (AY037928) wtEnv sequence. The 
consensus sequence and the putative original sequence (oricoEnv) obtained by applying an 
algorithm to identify shared polymorphisms (see results for details) are included. The 
consensus sequence and oricoEnv differ at positions 137, 369 and 676 due to shared 
polymorphisms (highlighted by rectangles). The eight sites in HERV-K113 wtEnv changed to 
the consensus sequence in order to reconstitute the ancestral protein sequence are in grey.  
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Fig. 4. Reconstitution of the ancient K113 oricoEnv sequence alters TM subunit processing. 
(A) Western blot analysis of coEnv-V5 and oricoEnv-V5 expressed in HEK 293T cells, Tera-
1 and HeLa cells. (B) Position of the potential glycosylation sites (NXS/T) within the Env 
molecule. The localization of the cleavage site (CS) and of amino acid changes resulting in 
oricoEnv are indicated. (C) PNGase F treatment of cell lysates from HeLa cells expressing 
coEnv-V5 and oricoEnv-V5. Lysates were incubated with and without PNGase F at 37 °C for 
1 h. Treated samples show a shift in the precursor and TM bands. (D) Incubation of HEK 
293T cells expressing oricoEnv-V5 with tunicamycin (30 and 50 µg/ml). The generation of a 
64 kDa N-terminal Env precursor degradation product (marked by an asterisk) is enhanced by 
tunicamycin treatment. (E) Elimination of the predicted glycosylation sites by mutagenesis 
results in a decrease in the molecular weights of the precursor and TM subunit and inhibits 













V5 the cleavage site sequence 461NRSKR was changed to 461NASAA. OricoEnv_CS/MMTV-
V5 carries a mutation (461NRS
13 
KR to 461NRAKR) that prevents potential glycosylation at 














Fig. 5. Incorporation of oricoEnv and C-terminal truncation mutants into lentiviral particles. 
(A) Amino acid sequences of the membrane spanning domain (boxed) and the cytoplasmic 
region are shown. The Env truncation mutants are named according to the number of amino 
acids deleted by the introduction of a stop codon (*). (B) The left hand panel shows an 
immunoblot of HEK 293T cells transfected with vectors used to produce pseudotyped SHIV 
reporter viruses plus the respective Env expression plasmids, visualized by a TM-ectodomain 
specific monoclonal antibody. Note the size shifts of the mutated TM subunits. The 
corresponding supernatants were collected, concentrated by ultracentrifugation through a 
sucrose cushion and also subjected to immunoblotting with the TM specific antibody (right 
















hand panel). Finally, the blot was stripped and incubated with an SIV Gag specific antibody 
to determine particle load. 
 
Fig. 6. Infectivity assay with pseudotyped SHIV reporter particles carrying a luciferase gene. 
The lentiviral particles were produced in HEK 293T cells, normalized and used to infect 
CrFK cells. 48 h later, cells were lysed and assayed for luciferase activity. The background 
level was determined by infection with a truncated non-functional HIV Env (KS). Mock 
treated cells were not infected. The means and standard deviations of six replicates are shown. 
Similar results were achieved in four independent experiments. 
 
Fig. 7. Impact of postinsertional mutations in the envelope protein of HERV-K113 on the 
entry efficiency of pseudotyped SHIV reporter viruses. (A) Mutations in the context of the C-
terminal truncation mutant with the highest entry level. (B) The substitutions have similar 
effects on the function of the full length oricoEnv. The means and standard deviations of six 
replicates are shown. Similar results were obtained in two independent experiments. 
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Fig. S1. Codon optimized sequence of the HERV-K113 env gene. 
 
Fig. S2. Table of mutagenesis primers used for generating oricoEnv, oricoEnvCS-, 
oricoEnvGly-, oricoEnv659-699, oricoEnv680-699, oricoEnv693-699 and coEnv 
mutants. 
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